Le Lézard
Classified in: Health, Science and technology
Subject: Conference

FORE Biotherapeutics to Participate in Upcoming Investor Conferences


FORE Biotherapeutics today announced that the Company, will participate at the following investor conferences:

Shawn M. Leland, PharmD, RPh, Interim Chief Executive Officer, and Jeffrey Sacher, Interim Chief Financial Officer, will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.

About Fore Biotherapeutics

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company's lead asset plixorafenib (FORE8394; PLX8394) is an inhibitor of BRAF dimerization allowing for the targeting of V600 and non-V600 driven tumors. In Phase 1/2a, plixorafenib demonstrated deep and durable responses in V600-mutated MAPK inhibitor-naïve patients, including a 42% overall response in patients with solid tumors with a median duration of response of 17.8 months and a 67% overall response rate in patients with primary central nervous system tumors with a median duration of response of 13.9 months. Plixorafenib is currently being investigated in the ongoing, potentially registrational Phase 2 FORTE study. For more information, please visit www.fore.bio or follow us on X (formerly Twitter) and LinkedIn.


These press releases may also interest you

at 11:00
PharmAla Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy
PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") , a biotechnology company focused on the research, development, and manufacturing of LaNeotm MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has...

at 11:00
MyAdvisor Opens New Office in Bedford County to Support Continued Growth
MyAdvisor, a holistic wellness company, is pleased to announce the opening of a new office in Bedford, Pennsylvania. This strategic expansion is driven by the company's sustained growth and commitment...

at 11:00
Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024 Meeting
Mozart Therapeutics, the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells. The data will be presented...

at 10:57
Toxic Drug Supply: The lived experience of those affected and a call to action
The toxic drug crisis that is now killing an average of 10 Ontarians every day will be the focus of a media conference organized by the Registered Nurses' Association of Ontario (RNAO) to close Nursing Week. While Nursing Week (May 6-12) is mainly...

at 10:53
Healthcare technology company co-founder highlights need for price transparency and innovative solutions at industry summit
Co-founder and CEO, Andrew Mignatti, of healthcare technology company, careviso, spoke at The Third Virtual National Health Care Transparency and No Surprises Act Summit. Mignatti's presentation centered around the existing transparency legislation...

at 10:45
New Transformative Leadership Team Announced for Texas Children's World-Renowned Heart Center
Texas Children's Hospital is pleased to announce the new executive leadership structure at the Texas Children's Heart Center, which has been ranked number one in the nation for pediatric cardiology and heart surgery by U.S. News and World Report for...

More news about Health...


News published on and distributed by: